This clinical trial focuses on the treatment of cancer using a medication called darolutamide. The study is designed for participants who have already been receiving darolutamide in previous studies sponsored by Bayer. Darolutamide is provided in the form of a film-coated tablet, and the purpose of this study is to continue the treatment for those who are benefiting from it.

Participants in this study will continue taking darolutamide as they have in their previous studies. The study aims to monitor the safety of darolutamide and observe any side effects that may occur during the treatment. The study does not involve any new medications or treatments, and participants will not receive a placebo.

The study will track the occurrence of any treatment-related side effects, including both common and serious ones. It will also look at how often the dosage of darolutamide needs to be adjusted. This study is open-label, meaning that both the participants and the researchers know that darolutamide is being administered. The study will continue until the estimated end date in 2025, allowing participants to maintain their treatment regimen as long as they continue to benefit from it.